Valar Labs and clinical partners published a peer-reviewed study in Urologic Oncology detailing the development and validation of an image-only AI prognostic biomarker for muscle-invasive bladder cancer (MIBC). Built on the company's Computational Histopathology Artificial Intelligence (CHAI) platform, the model extracts features from pre-treatment H&E-stained whole slide images to risk-stratify patients for recurrence-free, cancer-specific, and overall survival.
Our readClinical evidence is critical for evaluating AI diagnostics. This validation demonstrates that Valar Labs' underlying CHAI technology can derive meaningful prognostic signals from standard, already-collected pathology slides in MIBC patients, offering oncologists an additional data point for treatment planning without requiring separate molecular tests.